Back to Trades
Buy4
Insight Molecular Diagnostics Inc.
IMDX
Total Value
$3.0M
Net $3.0M bought
Purchases
$3.0M
2 transactions
Company Information
- Company Name
- Insight Molecular Diagnostics Inc.
- Ticker Symbol
- IMDX
- CIK
- 0001642380
Insider Information
- Role
- 10% Owner
- Location
- NEW YORK, NY
10% Owner
Filing Details
- Filing Date
- Feb 12, 2026
- Transaction Date
- Feb 10, 2026
- Accession Number
- 0000919574-26-000779
- Form Type
- 4
- Net Trading Amount
- $3.0M
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Feb 10, 2026 | Common Stock, no par value | 521,739 | $5.75 | Purchase | $3.0M |
| Feb 10, 2026 | Common Stock, no par value | — | — | Purchase | — |
Footnotes
- (F1)The reported securities are directly owned by Broadwood Partners, L.P. ("Broadwood Partners") and may be deemed to be beneficially owned by each of: (i) Broadwood Capital, Inc. ("Broadwood Capital"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher, as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
- (F2)These securities are directly owned by Neal C. Bradsher.
- (F3)On February 10, 2026, Broadwood Partners entered into a Securities Purchase Agreement with Insight Molecular Diagnostics, Inc. (the "Issuer") pursuant to which Broadwood Partners agreed to acquire 521,739 shares of the Issuer's Common Stock, no par value (the "Common Shares"), from the Issuer in a registered direct offering for a total purchase price of $2,999,999, or $5.75 per Common Share.
- (F4)These warrants are currently exercisable.